Why join Freenome?
Freenome is a high-growth biotech company developing tests to detect cancer using a standard blood draw. To do this, Freenome uses a multiomics platform that combines tumor and non-tumor signals with machine learning to find cancer in its earliest, most-treatable stages.
Cancer is relentless. This is why Freenome is building the clinical, economic, and operational evidence to drive cancer screening and save lives. Our first screening test is for colorectal cancer (CRC) and advanced adenomas, and it’s just the beginning.
Founded in 2014, Freenome has ~400 employees and continues to grow to match the scope of our ambitions to provide access to better screening and earlier cancer detection.
At Freenome, we aim to impact patients by empowering everyone to prevent, detect, and treat their disease. This, together with our high-performing culture of respect and cross-collaboration, is what motivates us to make every day count.
Become a Freenomer
Do you have what it takes to be a Freenomer? A “Freenomer” is a determined, mission-driven, results-oriented employee fueled by the opportunity to change the landscape of cancer and make a positive impact on patients’ lives. Freenomers bring their diverse experience, expertise, and personal perspective to solve problems and push to achieve what’s possible, one breakthrough at a time.
About this opportunity:
The Commercial Program Manager will be responsible for driving cross-functional teams to deliver complex commercial programs from conception through to completion. The role involves strategic planning, stakeholder management, and ensuring that all program deliverables are achieved on time, within budget, and to the highest standards. The Commercial Program Manager will work closely with Commercial and Product Management leaders to ensure timely and successful execution of commercial programs.
The role reports to the Senior Director of Program Management. This is a remote position that requires working during the company's business hours, 8 AM to 5 PM Pacific Time.
What you’ll do:
- Develop and implement program strategies, plans, and tactics across multiple projects, with a focus on commercial readiness and launch execution
- Coordinate and communicate between various departments, ensuring alignment with the company's strategic objectives
- Manage program budgets, timelines, resources, and risks
- Lead, motivate, and manage cross-functional teams to achieve program goals
- Establish and maintain relationships with key stakeholders, including customers, partners, and vendors
- Monitor program performance and implement adjustments as necessary to ensure success
- Prepare and present regular program reports to senior management and other stakeholders
- Ensure compliance with company policies, industry standards, and legal regulations
- Identify opportunities for continuous improvement and drive the implementation of best practices
Must haves:
- Bachelor's degree in Business, Management, Engineering, or a related field. Master’s degree or MBA preferred
- Minimum of 5 years of experience in program management, preferably in the medical device diagnostic industry
- Proven track record of managing complex commercial programs with cross-functional teams
- Strong leadership, communication, and interpersonal skills
- Excellent organizational, time management, and problem-solving abilities
- Proficient in Google Suite, Smartsheet and other program management software and tools
- Demonstration of leading complex trade-off decisions between functions
- Experience leading the development of decision frameworks and approaches to drive prioritization
- Demonstrated success in presenting to executive-level audiences to facilitate decision making
Nice to haves:
- PMP, PgMP, or equivalent certification is highly desirable
- Product launch experience
Benefits and additional information:
The US target range of our base salary for new hires is $140,250 - $216,500. You will also be eligible to receive pre-IPO equity, cash bonuses, and a full range of medical, financial, and other benefits depending on the position offered. Please note that individual total compensation for this position will be determined at the Company’s sole discretion and may vary based on several factors, including but not limited to, location, skill level, years and depth of relevant experience, and education. We invite you to check out our career page @ freenome.com/job-openings/ for additional company information.
Freenome is proud to be an equal-opportunity employer, and we value diversity. Freenome does not discriminate on the basis of race, color, religion, marital status, age, national origin, ancestry, physical or mental disability, medical condition, pregnancy, genetic information, gender, sexual orientation, gender identity or expression, veteran status, or any other status protected under federal, state, or local law.
Applicants have rights under Federal Employment Laws.
- Family & Medical Leave Act (FMLA)
- Equal Employment Opportunity (EEO)
- Employee Polygraph Protection Act (EPPA)
#LI-Remote
What We Do
Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent cancer.
We have pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw. By combining deep expertise in molecular biology with advanced computational biology and machine learning techniques to recognize disease-associated patterns among billions of circulating, cell-free biomarkers, we are developing simple and accurate blood tests for early cancer detection and integrating the actionable insights into health systems to operationalize a machine learning feedback loop between care and science.
Our recent $270 Million Series C brings our financing to over $500 million from investors, including; Bain Capital, Perceptive Advisors, RA Capital, Polaris Partners, Andreessen Horowitz, funds and accounts advised by T. Rowe Price Associates, Inc., GV (formerly Google Ventures), Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society’s BrightEdge Ventures, Data Collective Venture Capital, Novartis and Verily Life Sciences.